Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 + Chemotherapy + LDRT in First-line ES-SCLC
NCT06477523Phase 2Active, not recruiting
- Sponsor
- Sichuan University
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in small cell lung cancer (SCLC), sponsored by Sichuan University. Primary endpoints: Incidence of treatment-related adverse events at 48 months and Progression free survival at 6 months. Started May 2024; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06477523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06477523.